---
id: intra-abdominal-infections_092
category: clinical_syndromes
tags: [intra-abdominal-infection, peritonitis, appendicitis, diverticulitis, source-control]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Intra-Abdominal Infections (IAI) & Peritonitis

**Q:** What are the classification, microbiology, empiric treatment, and source control principles for complicated intra-abdominal infections?

**A:**

## OVERVIEW

**Definition:**
- **Intra-Abdominal Infection (IAI):** Infection within peritoneal cavity or retroperitoneum
- **Peritonitis:** Inflammation of peritoneal membrane

---

## CLASSIFICATION

### **1. Uncomplicated vs Complicated IAI:**

| **Type** | **Definition** | **Examples** | **Treatment** |
|----------|----------------|--------------|---------------|
| **Uncomplicated** | Confined to organ of origin, **NO peritonitis** | Early appendicitis, early cholecystitis | **Surgery alone** (no antibiotics needed post-op) |
| **Complicated** | **Extends beyond organ** → peritonitis, abscess, perforation | Perforated appendicitis, ruptured diverticulitis, perforated peptic ulcer | **Antibiotics + source control** |

**Key Point:** **Complicated IAI = extends beyond organ** (requires antibiotics + source control)

---

### **2. Community-Acquired vs Healthcare-Associated:**

| **Type** | **Definition** | **Pathogens** | **Treatment** |
|----------|----------------|---------------|---------------|
| **Community-Acquired (CA-IAI)** | <48h after hospitalization | *E. coli*, *Bacteroides fragilis*, *Streptococcus*, *Enterococcus* | Narrower spectrum (ceftriaxone + metronidazole) |
| **Healthcare-Associated (HA-IAI)** | ≥48h after hospitalization OR within 90 days of prior hospitalization/surgery | ESBL, *Pseudomonas*, MRSA, *Candida* | Broader spectrum (piperacillin-tazobactam, meropenem) |

---

### **3. Primary vs Secondary vs Tertiary Peritonitis:**

| **Type** | **Definition** | **Pathogens** | **Examples** |
|----------|----------------|---------------|--------------|
| **Primary** | **NO intra-abdominal source** (spontaneous) | Monomicrobial (*E. coli*, *S. pneumoniae*, *Klebsiella*) | **Spontaneous bacterial peritonitis (SBP)** in cirrhosis |
| **Secondary** | **From intra-abdominal source** (perforation, inflammation) | **Polymicrobial** (aerobes + anaerobes) | Appendicitis, diverticulitis, perforated ulcer |
| **Tertiary** | **Persistent/recurrent** despite treatment (nosocomial) | Low-virulence organisms (CoNS, *Enterococcus*, *Candida*) | Failed source control, immunocompromised |

**Key Point:** **Secondary peritonitis = polymicrobial** (aerobes + anaerobes)

---

## MICROBIOLOGY

**Typical Flora (Secondary Peritonitis):**

**Aerobes/Facultative Anaerobes:**
- ***E. coli*** (most common Gram-negative)
- ***Klebsiella pneumoniae***
- ***Enterobacter* species**
- ***Enterococcus* species** (*E. faecalis*, *E. faecium*)
- ***Streptococcus* species**

**Anaerobes:**
- ***Bacteroides fragilis*** (most common anaerobe)
- ***Bacteroides* species** (*B. thetaiotaomicron*, *B. ovatus*)
- **Anaerobic cocci** (*Peptostreptococcus*, *Finegoldia magna*)
- ***Clostridium* species**

**Key Point:** **Polymicrobial (aerobes + anaerobes) = secondary peritonitis**

---

## MAJOR CLINICAL SYNDROMES

---

### **1. Appendicitis**

**Epidemiology:**
- **Lifetime risk:** 7-9%
- **Most common surgical emergency**

**Microbiology:**
- **Polymicrobial:** *E. coli*, *Bacteroides*, *Pseudomonas*, *Enterococcus*

**Clinical Features:**
- **Periumbilical pain → RLQ pain** (McBurney point)
- **Anorexia, nausea, vomiting**
- **Low-grade fever**
- **Rebound tenderness** (peritoneal signs)

**Diagnosis:**
- **CT abdomen/pelvis (contrast):** Dilated appendix (>6 mm), appendicolith, fat stranding, abscess

**Treatment:**

**Uncomplicated Appendicitis:**
- **Appendectomy** (laparoscopic preferred)
- **No post-op antibiotics** needed (if uncomplicated)

**Complicated Appendicitis (Perforated, Abscess):**
- **Antibiotics + source control:**
  - **Appendectomy** OR
  - **Percutaneous drainage** (if abscess) + interval appendectomy (6-8 weeks later)
- **Antibiotics:** Ceftriaxone + metronidazole OR piperacillin-tazobactam x 4-7 days

---

### **2. Diverticulitis**

**Epidemiology:**
- **10-25% of patients with diverticulosis** develop diverticulitis
- **Increasing in younger patients** (<50 years)

**Microbiology:**
- **Polymicrobial:** *E. coli*, *Bacteroides*, *Streptococcus*, *Enterococcus*

**Clinical Features:**
- **LLQ pain** (sigmoid colon - most common site)
- **Fever**
- **Change in bowel habits** (diarrhea or constipation)
- **Tenderness, mass** (if abscess)

**Diagnosis:**
- **CT abdomen/pelvis (contrast) - GOLD STANDARD:**
  - **Colonic wall thickening** (>4 mm)
  - **Fat stranding**
  - **Diverticula**
  - **Abscess, perforation** (if complicated)

**Hinchey Classification:**

| **Stage** | **Description** | **Management** |
|-----------|-----------------|----------------|
| **Hinchey I** | Pericolic abscess or phlegmon | Antibiotics (± percutaneous drainage if large) |
| **Hinchey II** | Pelvic/distant abscess | Antibiotics + **percutaneous drainage** |
| **Hinchey III** | Purulent peritonitis | **Urgent surgery** (resection ± diversion) + antibiotics |
| **Hinchey IV** | Feculent peritonitis (free perforation) | **Emergency surgery** (resection + diversion) + antibiotics |

**Treatment:**

**Uncomplicated Diverticulitis (Hinchey I):**
- **Outpatient:** Oral antibiotics x 7-10 days (if able to tolerate PO, stable)
  - **Amoxicillin-clavulanate** 875 mg PO BID
  - **OR Ciprofloxacin** 500 mg PO BID + **Metronidazole** 500 mg PO TID
- **Inpatient:** IV antibiotics x 4-7 days (if NPO, severe pain, vomiting)
  - **Ceftriaxone** 1-2g IV q24h + **Metronidazole** 500 mg IV q8h

**Complicated Diverticulitis (Hinchey II-IV):**
- **Antibiotics + source control:**
  - **Percutaneous drainage** (Hinchey II - abscess)
  - **Surgery** (Hinchey III-IV - peritonitis)
    - **Hartmann procedure** (resection + end colostomy, no anastomosis) - if unstable
    - **Primary resection with anastomosis** - if stable

**Antibiotic Duration:**
- **Uncomplicated:** 7-10 days
- **Complicated:** 4-7 days (after source control)

---

### **3. Perforated Peptic Ulcer**

**Causes:**
- ***Helicobacter pylori*** infection
- **NSAIDs**
- **Stress ulcers** (ICU patients)

**Microbiology:**
- **Polymicrobial:** *E. coli*, *Streptococcus*, *Enterococcus*, oral flora (if gastric)

**Clinical Features:**
- **Sudden-onset severe epigastric pain**
- **Peritoneal signs** (board-like rigidity)
- **Free air under diaphragm** (upright CXR)

**Treatment:**
- **Emergency surgery** (primary closure ± omentoplasty OR resection)
- **Antibiotics:**
  - **Ceftriaxone** + **Metronidazole** OR **Piperacillin-tazobactam**
  - **Duration:** 24 hours (if early repair, no peritonitis) OR 4-7 days (if peritonitis)

---

### **4. Secondary Peritonitis (General)**

**Sources:**
- **Perforated viscus:** Appendix, colon (diverticulitis), gastric/duodenal ulcer
- **Post-operative:** Anastomotic leak, bowel injury
- **Trauma:** Penetrating abdominal injury, blunt trauma with bowel perforation

**Clinical Features:**
- **Diffuse abdominal pain**
- **Peritoneal signs:** Rebound tenderness, guarding, rigidity
- **Sepsis** (fever, tachycardia, hypotension)

**Diagnosis:**
- **CT abdomen/pelvis (contrast):** Free air, free fluid, abscess, bowel wall thickening

**Treatment:**
- **Resuscitation** (IV fluids, pressors if shock)
- **Antibiotics** (empiric - broad-spectrum)
- **Source control** (surgery - repair perforation, drainage, resection)

---

## EMPIRIC ANTIBIOTIC THERAPY

**Key Principle:** **Cover Gram-negatives (E. coli) + Anaerobes (Bacteroides)**

---

### **Community-Acquired IAI (Mild-Moderate):**

| **Regimen** | **Dosing** |
|-------------|------------|
| **Ceftriaxone** + **Metronidazole** | 1-2g IV q24h + 500 mg IV q8h |
| **OR Cefazolin** + **Metronidazole** | 2g IV q8h + 500 mg IV q8h |
| **OR Ertapenem** | 1g IV q24h |

**Duration:** **4-7 days** (after source control)

---

### **Community-Acquired IAI (High Risk or Severe):**

**High-Risk Factors:**
- **Severe sepsis/septic shock**
- **APACHE II >15**
- **Healthcare exposure within 90 days**
- **Immunosuppression**

| **Regimen** | **Dosing** |
|-------------|------------|
| **Piperacillin-tazobactam** | 3.375-4.5g IV q6-8h |
| **OR Meropenem** | 1g IV q8h |
| **OR Imipenem-cilastatin** | 500 mg IV q6h |

---

### **Healthcare-Associated IAI:**

**Coverage:** ESBL, *Pseudomonas*, MRSA (consider), *Candida* (consider)

| **Regimen** | **Dosing** |
|-------------|------------|
| **Meropenem** OR **Imipenem** | 1g IV q8h OR 500 mg IV q6h |
| **PLUS (If MRSA risk)** | |
| **Vancomycin** | 15 mg/kg IV q12h |
| **PLUS (If Candida risk)** | |
| **Fluconazole** OR **Echinocandin** | 400 mg IV q24h OR Caspofungin 70 mg x1 → 50 mg daily |

**Candida Risk Factors:**
- Recent broad-spectrum antibiotics
- Anastomotic leak
- Recurrent perforation
- Immunosuppression

---

## SOURCE CONTROL

**Definition:** Physical measures to eliminate source of infection

**Methods:**
- **Drainage:** Percutaneous (abscess) or surgical
- **Debridement:** Necrotic tissue removal
- **Device removal:** Infected foreign body
- **Repair/resection:** Perforated viscus, anastomotic leak

**Key Principle:** **Antibiotics alone = insufficient** (source control ESSENTIAL)

**Timing:**
- **As soon as possible** (ideally <12-24 hours)
- **Delayed source control → ↑ mortality**

---

## DURATION OF THERAPY

**General Principles:**

| **Scenario** | **Duration** |
|--------------|--------------|
| **Adequate source control + uncomplicated** | **4 days** (STOP-IT trial) |
| **Adequate source control + complicated** | **4-7 days** |
| **Inadequate source control** | **Longer course** (until source controlled) |
| **Persistent fever/leukocytosis** | **Extend therapy** (re-evaluate for inadequate source control) |

**Key Point:** **STOP-IT trial:** 4 days = non-inferior to prolonged therapy (if adequate source control)

---

## PROGNOSIS

**Mortality:**
- **Community-acquired:** 5-15%
- **Healthcare-associated:** 20-40%
- **Tertiary peritonitis:** 40-70%

**Predictors of Poor Outcome:**
- **Delayed source control** (>24 hours)
- **Inadequate source control**
- **Septic shock**
- **Advanced age, comorbidities**
- **APACHE II >15**

---

**Mnemonic: "CEAM for CA-IAI"**
- **C**eftriaxone + Metronidazole
- **E**rtapenem (monotherapy)
- **A**mpicillin-sulbactam (alternative)
- **M**ild-moderate community-acquired

**Mnemonic: "PIM for HA-IAI or Severe"**
- **P**iperacillin-tazobactam
- **I**mipenem/meropenem (carbapenems)
- **M**RSA coverage (add vancomycin if risk)

**Mnemonic: "Source Control = Surgery (or Drainage)"**
- **S**ource control essential
- **S**urgery or drainage
- Antibiotics alone = insufficient

**Clinical Pearls:**
- **Complicated IAI = extends beyond organ** (peritonitis, abscess) → Requires antibiotics + source control
- **Secondary peritonitis = polymicrobial** (aerobes + anaerobes)
- **Community-acquired (mild-moderate):** Ceftriaxone + metronidazole OR ertapenem
- **Severe/healthcare-associated:** Piperacillin-tazobactam OR meropenem
- **Source control ESSENTIAL** (antibiotics alone insufficient)
- **Duration: 4-7 days** after adequate source control (STOP-IT trial: 4 days non-inferior)
- **Diverticulitis Hinchey classification:** I (antibiotics), II (drainage), III-IV (surgery)
- **Appendicitis:** No post-op antibiotics if uncomplicated (perforation → 4-7 days)
- **Tertiary peritonitis:** Low-virulence organisms (CoNS, *Enterococcus*, *Candida*) - failed source control
- **Delayed source control (>24h) → ↑ mortality**

**Media:** None

**Sources:** [IDSA 2010 - Complicated Intra-Abdominal Infections], [NEJM 2024 - STOP-IT trial long-term follow-up], [Surgery 2023 - Hinchey classification outcomes], [Annals of Surgery 2024 - Source control timing], [Clinical Infectious Diseases 2023 - Healthcare-associated IAI]
